Innovative Product Focus Capillary Biomedical specializes in developing advanced insulin delivery devices, with its flagship SteadiSet infusion set designed for improved comfort and reliability, presenting opportunities to collaborate with healthcare providers and device distributors interested in cutting-edge diabetes management solutions.

Strategic Acquisition Being acquired by Tandem Diabetes Care, a major player in insulin delivery, enhances CapBio’s market reach and credibility, offering potential for partnership or B2B negotiations to access a broader customer base and integrated diabetes care solutions.

Academic Industry Collaboration The company’s roots in research at the Artificial Pancreas Center indicate ongoing innovation and a focus on improving insulin absorption consistency, which can be leveraged for co-development initiatives or to position as a research partner in new medical device innovations.

Funding and Growth Potential With recent seed funding of $2.9 million and projected revenue between one and ten million dollars, CapBio shows growth potential and willingness to invest in scaling distribution channels, creating opportunities for sales expansion and new partnership development.

Technology and Infrastructure Utilizing a modern tech stack, including cloud platforms and web interfaces, CapBio is well-positioned to integrate with digital health ecosystems, opening avenues for sales in healthcare IT integrations, remote monitoring systems, and digital services supporting diabetes care.